3rd PERMIT General Assembly
July 21, 2021

On 7 July, the PERMIT consortium met for its third General Assembly, to go over the achievements conducted over the past 6 months, and to discuss the activities for the next semester. In total nine different working sessions, focus groups and stakeholder consultations were held between February and July within work packages 3 to 6. 

Read more
Regulatory gaps in the personalised medicine pipeline
July 15, 2021

On 12 July, the PERMIT project held an online working session to discuss the regulatory gaps in the personalised medicine research pipeline. Gathering over 30 participants from within and beyond the PERMIT consortium, the session focused on the gaps and questions identified through the scoping reviews and consultation exercises. 

Read more
Study designs for clinical trials applied to personalised medicine
July 12, 2021

In July, PERMIT WP6 hosted two working sessions mainly focused on three specific trial designs commonly used in the field of personalised medicine (platform, umbrella and basket design). Experts in the field discussed how these three complex trial designs can be used for the development of personalised medicine, their advantages, and their disadvantages. 

Read more
Translational development phase in personalised medicine a focus group on in silico preclinical models
June 11, 2021

Shortly after the successful focus group to explore the industry perspective on preclinical research, the second working session on June 1st assessing the translational development phase looked at in silico models for personalised medicine. During this second meeting, the group, composed of five experts from the field, explored some common bottlenecks and potential solutions. The importance of high-quality data collection and sharing was debated, as well as the relevance of model validation for ensuring reliable results and regulation-related issues.

Read more